Nektar Therapeutics (NKTR) Return on Capital Employed (2011 - 2026)

Nektar Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 29.0% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 2566.0% year-over-year to 29.0% in Q1 2026; TTM through Mar 2026 was 29.0%, a 2566.0% increase from a year earlier, with the FY2025 full-year figure at 58.72%, down 2239.0% from the prior year.
• Return on Capital Employed rose to 29.0% in Q1 2026 per NKTR's latest filing, from 59.03% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 29.0% in Q1 2026 and bottomed at 71.48% in Q4 2023.
• The 5-year median for Return on Capital Employed is 59.03% (2025), against an average of 55.88%.
• Across the five-year window, Return on Capital Employed sank 2539 bps in 2022 and jumped 2846 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 55.51% in 2022, then retreated by 29 bps to 71.48% in 2023, then jumped by 40 bps to 43.02% in 2024, then tumbled by 37 bps to 59.03% in 2025, then soared by 51 bps to 29.0% in 2026.
• Per Business Quant, the three latest NKTR Return on Capital Employed figures stand at 29.0% (Q1 2026), 59.03% (Q4 2025), and 52.15% (Q3 2025).